Crowdsourced mapping of unexplored target space of kinase inhibitors

Anna Cichonska¹,²,³*, Balaguru Ravikumar¹*, Robert J Allaway⁴*, Sungjoon Park⁵, Fangping Wan⁶, Olexandr Isayev⁷, Shuya Li⁸, Michael Mason⁴, Andrew Lamb⁴, Zia-ur-Rehman Tanoli¹, Minji Jeon⁵, Sunkyu Kim⁵, Mariya Popova⁷, Stephen Capuzzi⁸, Jianyang Zeng⁶, Kristen Dang⁴, Gregory Koytiger⁹, Jaewoo Kang⁵, Carrow I. Wells¹⁰, Timothy M. Willson¹⁰, The IDG-DREAM Drug-Kinase Binding Prediction Challenge Consortium, Tudor I. Oprea¹¹, Avner Schlessinger¹², David H. Drewry¹⁰, Gustavo Stolovitzky¹³, Krister Wennerberg¹⁴, Justin Guinney⁴**, Tero Aittokallio¹,²,¹⁵,¹⁶,¹⁷**

*shared first authors
**shared last authors

Affiliations:
¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
²Department of Computer Science, Helsinki Institute for Information Technology (HIIT), Aalto University, Espoo, Finland
³Department of Future Technologies, University of Turku, Turku, Finland
⁴Computational Oncology, Sage Bionetworks, Seattle, WA, USA
⁵Department of Computer Science and Engineering, Korea University, Seoul, Republic of Korea
⁶Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China, 100084
⁷Department of Chemistry, Carnegie Mellon University, Pittsburgh, PA
⁸Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States
⁹Immuneering Corporation, Cambridge, MA, USA
¹⁰Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
¹¹Translational Informatics Division, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA
¹²Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA
¹³IBM T J Watson Research Center, IBM, Yorktown Heights, NY, USA
¹⁴Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark
¹⁵Department of Mathematics and Statistics, University of Turku, Turku, Finland
¹⁶Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
¹⁷Oslo Centre for Biostatistics and Epidemiology (OCBE), University of Oslo, Oslo, Norway
Abstract

Despite decades of intensive search for compounds that modulate the activity of particular proteins, there are currently small-molecule probes available only for a small proportion of the human proteome. Effective approaches are therefore required to map the massive space of unexplored compound-target interactions for novel and potent activities. Here, we carried out a crowdsourced benchmarking of the accuracy of machine learning (ML) algorithms at predicting kinase inhibitor potencies across multiple kinase families. A total of 268 ML predictions were scored in unpublished bioactivity data sets. Top-performing algorithms used kernel learning, gradient boosting and deep learning, with predictive accuracy exceeding that of target activity assays. Subsequent experiments carried out based on the the top-performing model predictions demonstrated that these models and their ensemble can improve the accuracy of experimental mapping efforts, especially for so far under-studied kinases. The open-source ML algorithms together with the novel dose-response data for 905 bioactivities between 95 compounds and 295 kinases provide a unique resource for extending the druggable kinome.

Introduction

Despite many years of target-based drug discovery, chemical agents inhibiting single protein targets are still rare.\(^1\) For instance, most approved drugs have multiple targets, suggesting their therapeutic efficacy as well as adverse side-effects originate from polypharmacological effects.\(^2\) Even if agents with narrow target profile often present with less toxic effects, multi-targeted approaches may provide improved efficacy for treating complex diseases. Systematic mapping of the target binding profiles is therefore critical not only to explore the therapeutic potential of promiscuous agents, but also to better predict and manage their possible adverse effects prior to further development and clinical trials (i.e., speeding-up and de-risking the drug development process). Novel off-target potencies of approved drugs could also extend the therapeutic application area of repurposed agents. However, the massive size of the chemical universe makes experimental mapping of the full space of compound-target interactions infeasible, even with automated high-throughput profiling assays.

To address this problem, we implemented the IDG-DREAM Drug-Kinase Binding Prediction Challenge, a crowd-sourced competition that evaluated the power of machine learning (ML) models as a systematic and cost-effective means for predicting novel compound-target potencies that warrant experimental evaluation (i.e., target prioritization). The Challenge focused on kinase inhibitors, since kinases are tractable in drug development and play a role in a wide range of diseases, such as cardiovascular disorders and cancers. However, protein kinase domains share structural and sequence similarity, and most kinase inhibitors bind to conserved ATP-binding pockets, which leads to prevalent target promiscuity and polypharmacological effects.\(^3\)–\(^5\) Such promiscuity requires effective target deconvolution approaches, including ML or
AI approaches, that can leverage the information extracted from similar kinases and compounds to predict the activity of so far unexplored interactions.

The Challenge was implemented in a screening-based, pre-competitive drug discovery project in collaboration with the NIH-supported Illuminating the Druggable Genome (IDG) program (https://commonfund.nih.gov/idg), with the common aim to establish kinome-wide target profiles of small-molecule agents, and thereby to extend the druggability of the human kinome space by providing activity information on under-studied proteins. The specific questions this Challenge sought to address were: (i) What are the best computational modelling approaches for predicting quantitative compound-target activity profiles?; (ii) What are the optimal molecular and chemical descriptors for maximal prediction accuracy?; and (iii) What are the most predictive bioactivity assays and publicly available datasets? The Challenge attracted 212 active participants, and a total of 268 predictions were scored, covering a wide range of ML approaches, including deep and kernel learning and gradient boosting decision trees. Here, we describe the benchmarking results from the Challenge, and the use of top-performing models for identifying novel kinase inhibitor activities.

Results

Challenge implementation
To develop their predictive models, the participants had access to a wide variety of bioactivity data for model training and cross-validation through open databases such as ChEMBL, BindingDB and IDG Pharos (Fig. 1). For training data collection, integration, management and harmonization, the Challenge made use of an open-data platform, DrugTargetCommons (DTC). DTC is a community platform that facilitates the annotation and curation of bioactivity data, and provides a comprehensive and standardized interface to retrieve compound-target profiles and related information to support predictive modelling (Suppl. Fig. 1). The Challenge infrastructure was built on the Synapse collaborative science platform, which supported receiving, validating and scoring of the teams’ predictions as well as long-term management of the test bioactivity data and submitted Challenge models as a benchmarking resource (Fig. 1).
Overview of the IDG-DREAM Drug-Kinase Binding prediction Challenge

Figure 1. Overview of the IDG-DREAM Drug-Kinase Binding prediction Challenge. The heatmap on the left is for illustrative purposes only (see Suppl. Fig. 2 for the actual test data matrices, and Suppl. Fig. 3 for the Challenge timeline).

Challenge test datasets

Evaluation of the model predictions was based on unpublished target activity data generated by the IDG Kinase Data and Resource Generation Center, conducted over a series of “rounds” based on availability of validation datasets (Suppl. Fig. 3). Generation of the test data for Round 1 was based on a single-dose kinome scan of a library of multi-targeted compounds. This was followed by a dose-response determination of the dissociation constant ($K_d$) values for 430 compound-kinase pairs between 70 inhibitors and 199 kinases that were not available in the public domain (see Methods). An additional set of completely new $K_d$ data was generated for Round 2, consisting of 394 multi-dose assays between 25 inhibitors and 207 kinases with single-dose inhibition $>$80%. Together, these 824 $K_d$ assays in the two Rounds spanned a total of 95 compounds and 295 kinases (Fig. 2A-B), consisting of promiscuous compounds targeting multiple kinases at low concentrations, compounds with narrow target profiles, as well as compounds with no potent targets among the tested kinases (Suppl. Fig. 2).

Round 1 enabled the teams to carry out initial testing of various model classes and data resources, whereas Round 2, implemented 6 months later, was used to score the final prediction models and to select the top-performing teams. Round 1 and 2 test data had very similar $K_d$ distributions (Fig. 2C), which provided comparable binding affinity outcome data to monitor the improvements made by the teams between the two rounds. Compounds in the test sets were mutually exclusive between rounds (Fig. 2A), with Round 2 including less selective...
compounds with broader target profiles (Fig. 2D), and therefore fewer inactive compound-target pairs ($pK_d = 5$). Round 1 and 2 kinase targets were partly overlapping, and covered all major kinase families and groups (Fig. 2B,E). Taken together, these two test datasets provided a standardized and sufficiently large quantitative bioactivity resource to evaluate the accuracy of predicting on- and off-target activities.

Figure 2. Challenge test datasets. (A) The overlap between Round 1 and Round 2 test compounds and kinases, and their distributions in the kinome tree (B) and across kinase groups (E). (C) The quantitative dissociation constant ($K_d$) of compound-kinase activities was measured in dose-response assays (see Methods), presented in the logarithmic scale as $pK_d = -\log_{10}(K_d)$. The higher the $pK_d$ value, the higher the inhibitory ability of a compound against a protein kinase (Suppl. Fig. 2 lists the compounds and kinases in Round 1 and Round 2). (D) The selectivity index for compounds was calculated based on the single-dose activity assay (at 1000 nM) across full compound-kinase matrices before the Challenge. The kinome tree figure was created with KinMap, reproduced courtesy of Cell Signaling Technology, Inc.
Overall performance of the models

The competition challenged the participants to predict blinded K_d profiles between 95 compounds and 295 kinases. A recently published and experimentally validated kernel regression approach for compound-kinase activity prediction was used as the “baseline model”\textsuperscript{12}. The accuracy of the predictions improved from Round 1 to Round 2 submissions as measured by Spearman correlation (two-sample Wilcoxon test, p<0.005; Fig. 3A) and Root Mean Square Error (RMSE, p<10^{-6}; Fig. 3C). Comparison against the baseline model indicated that the Round 2 dataset was marginally easier to predict (Suppl. Fig. 4), partly due to a smaller proportion of inactive pairs in Round 2 (pK_d = 5, Fig. 2C). To take into account this shift, we compared the submissions against a set of random predictions. Using Spearman correlation, we observed that 48% of the submission were better than random in Round 1, compared to 61% in Round 2 (Fig 3B). Using RMSE, 71% of the submissions in Round 1 were better than random, compared to 76% in Round 2 (Fig 3D).

The 20 teams that participated in both rounds improved their K_d predictions (p<0.05 and p<0.001 for Spearman and RMSE, paired Wilcoxon signed-rank test), but when comparing against the baseline model, the overall improvements became insignificant (p>0.05). However, there were individual teams (like Zahraa Sobhy) that were able to improve their predictions considerably between the two rounds. The practical upper bound of the model predictions was defined based on experimental replicates of K_d measurements (Fig. 3B,D). The predictive accuracy of the top-performing models in Round 2 was relatively high based on both of the winning metrics, Spearman correlation for rank predictions and RMSE for activity predictions; these metrics showed less correlated performance over the less-accurate models in Round 2 (Fig. 3F). The tie breaking metric, averaged area under the curve (AUC), provided complementary information on prediction accuracies when compared to RMSE but not to Spearman correlation (Suppl. Fig. 5).
Figure 3. Overall performance of the submissions. (A, C) Performance of the submissions in terms of the two winning metrics in Round 1 (n=169) and Round 2 (n=99). The colors mark the baseline model and top-performing participants in Round 2. The empty circles mark the submissions that did not differ from random predictions. The baseline model remained the same in both of the rounds. (B, D) Distribution of the random predictions (based on 10000 permuted pKᵋ values) and replicate distributions (based on 10000 subsamples with replacement of overlapping pKᵋ pairs between two large-scale target activity profiling studies) in Round 1.
(top panel) and Round 2 (bottom). The points correspond to the individual submissions. (E, F) Relationship of the two winning metrics across the submissions in Round 1 and Round 2. The shape indicates submissions based on deep learning in Round 2 (F). For instance, team DMIS_DK submitted predictions based on both random forest (RF) and deep learning (DL) algorithms in Round 2, where the latter showed slightly better accuracy (triangle). Overall, DL approaches did not perform better than the other learning approaches used in Round 2.

**Analysis of the top-performing models**

The top-performing models were selected in Round 2 based on 394 pK₄ predictions between 25 compounds and 207 kinases. Only those participants who submitted their Dockerized models, method write-ups and method surveys were qualified to win the two sub-challenges. To select the top-performers for the two winning metrics, Spearman correlation and RMSE, we conducted a bootstrap analysis of each participant’s best submission, and then calculated a Bayes factor (K) relative to the bootstrapped overall best submission for each winning metric (Suppl. Fig. 6). Considering Spearman correlation, the top-performer was team Q.E.D (K<3; Fig. 4A). For the RMSE metric, the top-performing teams were AI Winter is Coming (AIWIC) and DMIS_DK (K<3; Suppl. Fig. 6), with AIWIC having a marginally better tie-breaking metric (average AUC of 0.773; Fig. 4B). Only two non-qualifying participants (Gregory Koytiger and Olivier Labayle) showed a comparable performance. Overall, these five teams performed the best when considering the 54 teams in Round 2 (Suppl. Fig. 7).
Figure 4. Top-performing models and their ensemble combination. (A) Spearman correlation sub-challenge top-performer in Round 2, Q.E.D. (B) RMSE sub-challenge top-performer in Round 2, AI Winter is Coming. (C) Ensemble model that combines the top four models selected based on their Spearman correlation in Round 2. The points correspond to the 394 compound-kinase pairs between 25 inhibitors and 207 kinases in Round 2. (D) The mean aggregation ensemble model was constructed by adding an increasing number of top-performing models based on their Spearman correlation, until the ensemble correlation dropped below 0.45. The peak performance was reached when aggregating four teams (marked in the legend, see Suppl. Fig. 8 for names of all the teams).
Notably, the top-performing models were based on various ML approaches, including deep learning, graph convolutional networks, gradient boosting decision trees, kernel learning and regularized regression (Table 1). To study whether combining predictions from multiple ML approaches could improve prediction accuracy, we constructed an ensemble model by simple mean aggregation of an increasing number of top-performing models in Round 2. The combination of the four best performing models resulted in the peak Spearman correlation (Fig. 4C), demonstrating complementary value of these predictions. After adding more models, the ensemble prediction accuracy started to decrease rather rapidly, both in terms of Spearman correlation and RMSE (Fig. 4D). However, an ensemble prediction from a total of 21 best teams had a significantly better correlation than the best single model alone (K>5; Suppl. Fig. 8). This suggests that combination of various ML approaches using an ensemble model leads to accurate and robust predictions of kinase inhibitor potencies across multiple kinase families.

| **Team**         | Algorithm Type       | Algorithm Names          | Combined Models | Training Strategy                  |
|------------------|----------------------|--------------------------|----------------|-----------------------------------|
| DMIS_DK          | Deep learning        | Graph Neural Networks    | 12             | Train test split                  |
| AI Winter is     | Gradient boosting    | XGboost                  | 5 per target   | K-fold nested cross validation    |
| Coming           | decision trees       |                          |                |                                   |
| Q.E.D            | Kernel learning      | CGKronRLS                | 440            | Boosting                          |
| Gregory Koytiger | Deep learning        | Not applicable           | 6              | Fixed hold out                    |
| Olivier Labayle  | Ridge regression     | Not applicable           | Not applicable | K-fold cross validation           |
| Baseline         | Kernel learning      | CGKronRLS                | 1              | K-fold nested cross validation    |

Table 1. Characteristics of the Round 2 top-performing methods and the baseline model. 

| **Team**         | Training Data Sources | Compound-Protein Pairs | Bioactivity Types | Protein Representation | Chemical Representation |
|------------------|-----------------------|------------------------|-------------------|------------------------|-------------------------|
| DMIS_DK          | DrugTargetCommons, BindingDB | 953521 | K_d, K_i, IC_{50} | None | 2D molecular graphs |
| AI Winter is     | DrugTargetCommons, ChEMBL | 600000 | K_d, K_i, IC_{50}, EC_{50} | None | ECFP5, ECFP7, ECFP9, ECFP11 |
| Coming           | DrugTargetCommons, ChEMBL, Uniprot | 60462 | K_d, K_i, EC_{50} | Amino acid sequences | ECFP4, ECFP6 |
| Q.E.D            | DrugTargetCommons, ChEMBL, Uniprot | 250000 | K_d, K_i, IC_{50} | None | None |
| Gregory Koytiger | DrugTargetCommons, ChEMBL, Uniprot | 18200 | K_i | K-mer counting | ECFP |
| Olivier Labayle  | DrugTargetCommons, ChEMBL, Uniprot | 44186 | K_i | Amino acid sequences | Path-based fingerprints |
| Baseline         | DrugTargetCommons | | | | |
Comparison against single-dose activity

We next investigated how well the top-performing ML models compare against the single-dose activity assays when predicting the pK\textsubscript{d} measurements. The practical problem of many target screening studies is how to reduce the number of false positives and false negatives when selecting most potent compound-target activities for more detailed, multi-dose K\textsubscript{d} profiling. For this classification task, we defined the ground truth activity classes based on the measured K\textsubscript{d} potencies, which provide a more direct prediction outcome, compared to the rank correlation analyses that already demonstrated predictive rankings from the top-performing models (Fig. 4).

Using the activity cut-off of measured pK\textsubscript{d} = 6 and an single-dose inhibition cut-off of 80%, similar to previous studies\textsuperscript{5,11,13} the positive predictive value (PPV) and the false discovery rate (FDR) of the single-dose assay were PPV = 0.66 and FDR = 0.44 in the Round 2 dataset. When using the mean aggregation ensemble of the predicted pK\textsubscript{d} values from the top-performing models and the same cut-off of pK\textsubscript{d} > 6 for both the predicted and measured activities, we observed an improved precision of PPV = 0.76 and FDR = 0.24.

We further repeated the activity classification with multiple cut-off levels, and ranked the Round 2 pairs both using the model-predicted pK\textsubscript{d} values and the measured single-dose inhibition assay values, and then compared these rankings against the measured dose-response assay (pK\textsubscript{d} > 6 indicates positive activity class). The ROC analyses demonstrated an improved activity classification accuracy using the mean ensemble of the top-performing models (Fig. 5A), especially when focusing on the most potent compound-target activities with the highest specificity that are important in practice when prioritizing a subset of most potent activities for multi-dose validation. This improvement in both sensitivity and specificity was achieved without making any additional activity measurements, and it became even more pronounced with the precision-recall analysis, which showed that the precision of the prediction models remained above PPV\textsuperscript{=}75\% level even when the recall (sensitivity) level exceeded 75\% (Fig. 5B). As expected, the prediction accuracy decreased when using more stringent activity cut-off of pK\textsubscript{d} > 7 (Suppl. Fig. 9), since these extreme activities are more challenging to predict.
Figure 5. Top-performing model predictions compared against single-dose assays. (A) Receiver operating characteristic (ROC) curves when ranking the 394 compound-kinase pairs from Round 2 using both the ensemble of the top-performing models (average predicted $pK_d$ from Q.E.D, DMIS_DK and AI Winter is Coming) and the experimental single-dose inhibition assays (the true positive activity class includes pairs with measured $pK_d > 6$). The area under ROC curve values are shown in the parentheses and the diagonal dotted line shows the random prediction accuracy of AU-ROC=0.50. (B) Precision-recall (PR) curves for the same activity classification analysis as shown in panel A. The area under the PR curve values are shown in parentheses and the horizontal dotted line indicates the precision of 0.75 level. Sensitivity=Recall. Precision=PPV.

Since the Round 2 multi-dose $K_d$ measurements were pre-selected among all the 5100 compound-kinase pairs to include mostly those pairs with single-dose inhibition>80%, Round 2 dataset enables systematic analysis of false positive predictions made based on single-dose assays or model predictions. However, these 394 pairs selected for $K_d$ profiling were more limited for a comprehensive analysis of false negative predictions (i.e., those with measured $pK_d > 6$, but single-dose inhibition<80% or predicted $pK_d < 6$). This means that the above comparison between single-dose inhibition assays and model-predicted $pK_d$ is biased in the sense that the inhibition values were used to select the pairs for the Round2 $K_d$ profiling, which therefore misses the more challenging compound-kinase pairs that had lower single-dose inhibition. This is why in the next section we carried out further experimental validations of the model-predicted $pK_d$ profiles in a more unbiased manner to investigate false negative predictions from both single-dose assays and ML models.
Model-based target predictions

To explore the compound-kinase pairs across the full spectrum of single-dose inhibition levels, we experimentally profiled 81 additional pairs, which were not part of Round 1 or 2 datasets, based solely on the pK$_d$ predictions from the three top-performing models. These follow-up experiments were carried out in an unbiased manner, regardless of the compound class or selectivity, kinase target families, or inhibition levels of the pairs, to investigate whether it is possible to use predictive models to identify potent inhibitors of kinases showing less than 80% single-dose inhibition; this activity cut-off is often used when selecting pairs for multi-dose K$_d$ testing $^5,11,13$. Most of the measured pK$_d$ values of these 81 pairs were distributed as expected, according to the expected single-dose inhibition function (Fig. 6A, black trace). However, this model-based approach also identified unexpected activities (pK$_d$ > 6) that could not be predicted based on the inhibition assay only; those with pK$_d$ > 7 are discussed below.

As an example of a potent activity missed by the single-dose assays, the top-performing models predicted PYK2 (PTK2B) as a high affinity target of a PLK inhibitor TPKI-30 (Fig. 6A). The new multi-dose pK$_d$ measurements validated that TPKI-30 indeed has an activity against PYK2 close to its potency towards PLK2 (Fig. 6B, left panel). This is rather surprising and novel result that a PLK inhibitor targets PYK2, and with a somewhat lesser potency also its paralog, FAK (PTK2). Neither PYK2 or FAK would have been predicted to be potent targets based on the single-dose testing alone, which led to multiple false negatives (Fig. 6B, right panel). Similarly, the single dose-testing had a relatively low predictivity of actual potencies for TPKI-30, since kinases other than PLKs with high single-dose activity were reported as non-potent targets based on dose-response K$_d$ testing, resulting in false positives. In contrast, the model predictions turned out to be relatively accurate, except for a few receptor tyrosine kinases (Fig. 6B, left panel).

Another unexpected target activity was predicted for GSK1379763 that showed high potency against DDR1 based on the K$_d$ assays, exceeding that of the AURKB (Fig. 6C, left panel). The single-dose testing suggested that this compound would not have potency against DDR1 or AURKB (Fig. 6C, right panel), whereas multi-dose assays confirmed potency towards DDR1 at a higher level as against the Round 2 highest affinity target MEK5 (MAP2K5). Notably, both of these high affinity predicted targets, PYK2 and DDR1, are less-explored kinases with only a few bioactivity data values available in DTC or ChEMBL. This suggests that the prediction models can identify potent inhibitors for under-studied kinases that would have been missed when using single-dose assays alone. The third high predicted activity between AKI00000050a and FLT1 could have been predicted based on its relatively high single-dose activity (Fig. 6A). This compound was confirmed to be a potent KDR (FLT2) inhibitor with quite similar potency as that against FLT1.
Figure 6. Machine learning-based target predictions. (A) Comparison of single-dose inhibition assay (at 1 µM) against multi-dose K\textsubscript{d} assay activities across 475 compound-target pairs (394 Round 2 pairs and 81 additionally profiled pairs). The red points indicate false negatives and blue points false positives when using cut-offs of pK\textsubscript{d} = 6 and inhibition=80% among the Round 2 pairs (including 75 pairs with inhibition>80% but that showed no activity in the dose-response assays, i.e, pK\textsubscript{d} = 5). The green points indicate the new experimental validations based solely on model predictions, regardless of inhibition levels. Both the single-dose and dose-response assays were carried out as competitive binding assays similar to previous studies. The black trace indicates the expected %inhibition rate based on measured pK\textsubscript{d}'s, estimated using the maximum ligand concentration of 1 µM both for the single-dose and dose-response assays. (B) Multi-dose (left) and single-dose (right) assays for kinases tested with TPKI-30. Green points indicate the new experimental validations based on model predictions, whereas black points come from Round 2 data. Blue points indicate false positive predictions based either on predictive models or single-dose testing. Single-dose testing predicted TPKI-30 to be relatively potent PLK1/2/3 inhibitor, whereas the dose-response testing confirmed it as PLK1 selective. (C) Multi-dose (left) and single-dose (right) assays for kinases tested with GSK1379763. Green points indicate the new experimental validations based on model predictions, whereas black points come from Round 2 data. Blue points indicate false positive predictions based either on predictive models or single-dose testing. (D) Predictive
accuracy of the ensemble of top-performing models (average predicted pK_d) and single-dose assay (at 1 µM) when classifying various subsets of 475 pairs into those with measured pK_d less or higher than 6. The y-axis indicates the area under the receiver operating characteristic curve (AUC) as a function single-dose inhibition cut-off levels, x-axis indicates the pairs with inhibition>x%, and the dotted black curve the percentage of all pairs that passed that activity cut-off threshold. The combined model trace corresponds to the average of measured and expected inhibition values, where the latter was calculated based on the mean ensemble of the top-performing model pK_d predictions (Q.E.D., DMIS_DK and AI Winter is Coming). (E) Receiver operating characteristic (ROC) curves (left) and precision-recall (PR) curves (right), when ranking all the 475 pairs either using the top-performing model-predicted pK_d values or the measured single-dose inhibition assays (the true positive activity class includes pairs with measured pK_d > 6). The AUC values are shown in parentheses, and the diagonal dotted line indicates the random prediction accuracy of AU-ROC=0.50 (left), and the horizontal dotted line indicates the precision level of 0.75 (right). Sensitivity=Recall. Precision=PPV.

Surprisingly, the single-dose inhibition assays and model-based pK_d predictions were almost uncorrelated (Suppl. Fig. 10, Spearman correlation 0.24), and they showed opposite trends for K_d prediction accuracy when increasing the inhibition cut-off level (Fig. 6D). To combine these two activity estimators, we calculated for each compound-kinase pair an average of the measured and expected inhibition values based on the single-dose assay and the top-performing models, respectively. This combined predictor showed improved activity classifications beyond that of the model predictions alone, across various inhibition levels, and identified a larger number of potent compound-target interactions with lower single-dose activity, compared to the standard 80% cut-off (Fig. 6D, dotted line). The combined model improved both the sensitivity and specificity of the pK_d predictions among all the 475 pairs (Fig. 6E, left panel), and especially the precision of the top-activity predictions that are prioritized for further experimental validation (Fig. 6E, right panel).

Discussion
Experimental mapping of compound-target interactions is critical for understanding compounds’ mode of action (MoA), but biochemical target activity profiling experiments are both time consuming and costly. Moreover, the enormous size of the chemical universe, estimated to consist of approximately 10^20 molecules exhibiting good pharmacological properties, makes experimental bioactivity mapping of the full compound and target space quickly infeasible in practice. ML models are aimed at guiding data-driven decision making, and these models have shown potential to reduce failure rates and accelerate several phases of drug discovery and development. The IDG-DREAM Drug Kinase Binding Prediction Challenge sought to benchmark state-of-the-art ML algorithms in the task of exploring the druggable kinome space by combining predictive modelling with experimental target activity profiling. In particular, the Challenge participants applied supervised ML models in the task of guiding biochemical mapping efforts by systematic prioritization of the most potent compound-target activities for further experimental evaluation. The ML model-guided approach has the potential to help both
(i) phenotype-based drug discovery (e.g. mapping the active target space of lead compounds), and (ii) target-based drug discovery (e.g. identification of candidate compounds that selectively inhibit a particular disease-related target).

Although previous work has already demonstrated the potential of ML algorithms for filling in the gaps in existing drug-target interaction maps, there are no systematic benchmarking comparisons of the algorithms in blinded, comprehensive datasets. The participants were therefore encouraged to explore various statistical and machine learning modelling approaches. In the Round 2 results, no particular method class, training data source or bioactivity type stood out. Rather, the top-performing teams used relatively different approaches (Table 1). Some of the top-performing models used protein sequence as target feature, but no structural information. Furthermore, none of the top-performing models require 3D or other detailed chemical information, making the ML models rather straightforward to apply for many compound and target classes. Recently, many advanced deep learning (DL) algorithms have been proposed for compound-target interaction prediction, but our results did not find DL outperforming other learning approaches. The Spearman correlation sub-challenge top-performer (Q.E.D) actually used the same modelling approach as the baseline model, yet showing markedly better performance (Fig. 3F), indicating that careful feature selection, method implementation, or other domain knowledge, could result in marked performance improvement. A number of other models also outperformed the baseline model in Round 2 (Suppl. Fig. 7).

To get a more global picture, at the end of the Challenge we asked all the teams to fill in survey questionnaires to explore whether there would be any broad method classes or chemical or target features shared among the models. Among the 31 teams that answered the surveys, none of the method classes had a very strong contribution to the accuracy (Suppl. Fig. 11), similarly as has been seen also in other DREAM challenges. A rather surprising observation from the survey was that the $K_{i}$ prediction accuracies could be somewhat improved by using also other types of multi-dose bioactivity data (e.g. $K_{i}$, $IC_{50}$, $EC_{50}$), compared to using $K_{i}$ data alone (Suppl. Fig. 11). This provides a further opportunity for ML models that often require relatively large training datasets, as these bioactivity types are among the most common ones so far used in multi-dose target profiling, and more common than $K_{i}$ in DTC database (Suppl. Fig. 11G). Another observation was that the teams that used DTC alone as training bioactivity data source tended to have somewhat decreased predictive accuracy, perhaps because of more heterogeneous bioactivity data stored in DTC, compared to BindingDB or ChEMBL. This suggests that further annotation and harmonization of the various types and sources of bioactivity data will be needed to make the most of these data for predictive modelling, ideally in the form of a crowdsourced community effort.

Many previous DREAM Challenges have demonstrated that ‘wisdom of the crowds’ may also improve the predictive power of the individual models through combining the models as meta-predictors or ensemble models. The ensemble model constructed in this Challenge based on the Round 2 submissions showed that the critical point came rather quickly after which adding more models led to rather rapid decrease in accuracy (Fig. 4D). This suggests that in
drug-target interaction prediction a better strategy may be to use merely the ‘wisdom of the best teams’. The combination of the top-performing ML models improved both the sensitivity and specificity, compared to single-dose target activity assays, without requiring any additional experiments (Fig. 5). None of the top-performing models used single-dose inhibition assay data, and we showed how by combining the inhibition measurements with ML models, one can reach higher prediction accuracy than using either one alone, while identifying an increased number of potent compound-kinase activities than when using the standard 80% inhibition cut-off (Fig. 6). The best-performing models were not dependent on the number or type of available bioactivity data, provided the training data have sufficient structural diversity for the kinase families being predicted. Subsequent experiments carried out based on the the top-performing model predictions demonstrated that these models can guide the experimental mapping efforts, especially for so far under-studied kinases (Fig. 6B,C).

To enable the community to apply the ML models benchmarked in the Challenge to various drug development applications, we have made available the top-performing prediction models as containerized source code. Such Docker models enable continuous validation of the model predictions whenever new experimental kinase profiling data will become available, as well as enable the researchers to run the best performing models on private data that would otherwise remain closed and unavailable to the research community. This Challenge will, therefore, contribute to the further development and benchmarking of the current and future target activity prediction models on a much larger scale and for various precision medicine applications. For instance, for the prediction of selective inhibitors for new kinase targets, or off-target potency predictions for new investigational compounds. All the prediction models, new bioactivity data, and benchmarking infrastructure are openly available either on Synapse (www.doi.org/10.7303/syn15667962) or via DTC open-data platform (https://drugtargetcommons.fimm.fi/). We envision that the IDG-DREAM Challenge will provide a continuously-updated resource for the chemical biology community to prioritize and experimentally test new target activities toward accelerating many drug discovery and repurposing applications.

Online Methods

Challenge infrastructure and timeline
The Challenge was organized and run on the collaborative science platform Synapse. All prediction files were submitted using the Challenge feature of this platform to track which teams and individuals submitted files, and to track the number of submissions per team. Challenge infrastructure scripts including code for calculating the scoring metrics are available at https://github.com/Sage-Bionetworks/IDG-DREAM-Drug-Kinase-Challenge. Teams were permitted to submit three predictions for Round 1, and two predictions for Round 2 (Suppl. Fig. 3). For Rounds 1 and 2, we used a common workflow language-based challenge infrastructure to perform the following tasks: (1) validate a prediction file to ensure that it conformed to the correct file structure and had numeric pKi predictions and return an error email to participants if
invalid, (2) run a python script to calculate the performance metrics for a submitted prediction, and (3) return the score to the Synapse platform. For Round 1b, in which we permitted 1 submission a day for 60 days, we implemented a modified Ladderboot protocol to prevent model overfitting. This was done by modifying step (2) above as follows: the scoring infrastructure receive a submitted prediction, check for a previous submission from the same team, and run an R script to bootstrap the current and previous submission 10000 times, calculate a Bayes factor (K) between the two submissions; the scoring harness would then only return an updated score if it was substantially better (K > 3) than the previous submission.

Bioactivity data for model testing

To generate unpublished test bioactivity data for scoring of predictions, we sent kinase inhibitors to DiscoverX (Eurofins Corporation) for the generation of new dose-response dissociation constant (K_d) values, as a measure of a binding affinity. In order to give a better sense of the relative compound potencies, K_d is represented in the logarithmic scale, as pK_d = -log_{10}(K_d), where K_d is given in molars [M]. The higher the pK_d value, the higher the inhibitory ability of a compound against a protein kinase. The 105 inhibitors used in the Challenge (70 for Round 1 and 25 for Round 2) were a part of the kinase inhibitor collection at the SGC-UNC for which we already had the single-dose inhibition screening done at DiscoverX across their large kinase panel. This scanMax data (also called KINOMEScan) was collected at a screening concentration of 1 µM. A two-step screening approach was adopted, similar to the previous studies, using the DiscoverX KINOMEScan standard protocol. The dose-response K_d values were generated for a range of compound-kinase pairs that had inhibition>80% in the single-dose assay. The compounds were supplied as 10 mM stocks in DMSO, and the top screening concentration was 10 mM.

25 of the axitinib-kinase pairs generated for Round 2 were already profiled in previous published studies, and were therefore excluded from the Round 2 dataset. The Spearman correlation between these newly-measured pK_d's and those available from DTC was 0.701 (Suppl. Fig. 12A), providing the experimental consistency of the K_d measurements for axitinib. We note this 25 pK_d's is a rather limited set for such analysis of consistency, and therefore we extracted a larger set of 416 K_d values that overlapped with the Round 2 kinases from two comprehensive target profiling studies including 104 pairs where pK_d = 5 in both of the studies. The Spearman correlation of these replicate pK_d measurements was 0.842 (Suppl. Fig. 12B), demonstrating a good reproducibility of the pK_d measurements. These replicate measurements were also used when determining a practical upper limit for the predictive accuracy of the machine learning models in the scoring of their predictions (see below).

To subsequently test the top-performing model predictions in additional compound-kinase pairs that were not part of Round 1 or 2 datasets, we selected a set of 88 pairs that showed most potency based on the average predicted pK_d of the top-performing models (Q.E.D., DMIS-DK and AIWIC), regardless of their single-dose inhibition levels. These 88 pairs were scattered across the whole spectrum of single-dose inhibition levels, ranging from 0% to 78%
Supplementary Fig. 10; note: pairs with inhibition >80% were \( K_D \)-profiled already in Round 2). One of the compounds (TPKI-35) was not available from IDG, so the predicted 7 kinase targets for that compound could not be tested experimentally, resulting in a dataset of total of 81 compound-kinase pairs that were shipped to DiscoverX for multi-dose Kd profiling. One of the compounds (GW819776) was shipped separately in a tube, whereas the other 14 compounds were supplied as 10 mM stocks in DMSO, and the Kd profiling done was done using the same KINOMEscan competitive binding assay protocol as for the Round 1 and Round 2 pairs.

**Scoring of the model predictions**

We used the following six metrics to score the predictions from the participants:

- Root-mean-square error (RMSE): square root of the average squared difference between the predicted \( pK_D \) and measured \( pK_D \), to score continuous activity predictions.
- Pearson correlation: Pearson correlation coefficient between the predicted and measured \( pK_D \)'s, which quantifies the linear relationship between the activity values.
- Spearman correlation: Spearman's rank correlation coefficient between the predicted and measured \( pK_D \)'s, which quantifies the ability to rank pairs in correct order.
- Concordance index (CI): probability that the predictions for two randomly drawn compound-kinase pairs with different \( pK_D \) values are in the correct order.
- F1 score: the harmonic mean of the precision and recall metrics. Interactions were binarized by their \( pK_D \) values into positive class (\( pK_D > 7 \)) and negative class (\( pK_D \leq 7 \)).
- Average AUC: average area under ten receiver operating characteristic (ROC) curves generated using ten interaction threshold values from the \( pK_D \) interval [6, 8] to binarize \( pK_D \)'s into true class labels.

The submissions in Round 1 were scored across the six metrics but the teams remained unranked. The Round 2 consisted of two sub-challenges, the top-performers of which were determined based on RMSE and Spearman correlation, respectively. Spearman correlation evaluated the prediction in terms of accuracy at ranking of the compound-kinase pairs based on the measured \( K_D \) values, whereas RMSE considers the absolute errors in the quantitative binding affinity profiles. The tie-breaking metric for both Rounds was averaged area under the curve (AUC) metric that evaluated the accuracy of the models to classify the \( pK_D \) values into active and inactive classes based on multiple \( K_D \) thresholds.

**Statistical evaluation of the predictions**

Determination of the top-performers was made by calculation of a Bayes factor relative to the top-ranked submission in each category. Briefly, we bootstrapped all submissions (10000 iterations of sampling with replacement), and calculated RMSE and Spearman correlation to the test dataset to generate a distribution of scores for each submission. A Bayes factor was then calculated using the challengescoring R package (https://github.com/sage-bionetworks/challengescoring) for each submission relative to the top submission in each subchallenge. Submissions with a Bayes factor <= 3 relative to the top submission were considered to be tied as top-performers. Tie breaking for both subchallenges was performed by identifying submission with the highest absolute average AUC.
To create a distribution of random predictions, we randomly shuffled the 430/394 Kd values across the set of 430/394 compound-kinase pairs in the Round 1/Round 2 datasets, and repeated the permutation procedure 10000 times. Then we compared the actual Round 1/Round 2 prediction scores to Spearman and RMSE calculated from the permuted Kd data. We defined a prediction as better than random if its score was higher than the maximum of the 10000 random predictions (empirical p=0.0, permutation test).

To determine the maximum possible performance practically achievable by any computational models, we utilized replicate Kd measurements from distinct studies that applied a similar biochemical assay protocol. We used the DrugTargetCommons to retrieve 863 and 835 replicated Kd values for kinases or compounds that overlapped with the Round 1 and 2 datasets, respectively. These data originated from two comprehensive screening studies\(^3,4\). To better represent the distribution of pKd values in the test data, we subset the DTC data to contain 35% (Round 1) and 25% (Round 2) pKd=5 values, approximately matching the proportion of pKd = 5 values in R1 and R2 test sets. For Round 1, we used 317 replicated Kds, including 111 randomly selected pairs where pKd = 5. For Round 2, we used 416 replicated Kds, including 104 randomly selected pairs where pKd = 5. We randomly sampled the replicate measurements of these compound-kinase pairs (with replacement), calculated the Spearman correlation and RMSE between the Davis and Fabian pKd’s for each 430 and 394 sub-sampled sets for Round 1 and 2, respectively, and repeated this procedure for a total of 10000 samplings.

**Baseline model**

We used a recently-published and experimentally-validated kernel regression framework as a baseline model for compound-kinase binding affinity prediction\(^12\). Our training dataset consisted of 44186 pKd values (between 1968 compounds and 423 human kinases) extracted from DTC. Median was taken if multiple pKd measurements were available for the same compound-kinase pair. We constructed protein kinase kernel using normalized Smith-Waterman alignment scores between full amino acid sequences, and four Tanimoto compound kernels based on the following fingerprints implemented in rcdk R package\(^23\): (i) 881-bit fingerprint defined by PubChem (pubchem), (ii) path-based 1024-bit fingerprint (standard), (iii) 1024-bit fingerprint based on the shortest paths between atoms taking into account ring systems and charges (shortestpath), and (iv) extended connectivity 1024-bit fingerprint with a maximum diameter set to 6 (ECFP6; circular). We used CGKronRLS as a learning algorithm\(^24\) (implementation available at https://github.com/aatapa/RLScore). We conducted a nested cross-validation in order to evaluate the generalisation performance of CGKronRLS with each pair of kinase and compound kernels as well as to tune the regularisation hyperparameter of the model. In particular, since the majority of the compounds from the Challenge test datasets had no bioactivity data available in the public domain, we implemented a nested leave-compound-out cross-validation to resemble the setting of the Challenge as closely as possible. The model comprising of protein kernel coupled with compound kernel built upon path-based fingerprint (standard) achieved the highest predictive performance on the training dataset (as measured by RMSE), and therefore it was
used as a baseline model for compound-kinase binding affinity prediction in both Challenge Rounds.

**Top-performing models**

Supplementary write ups provide details of all qualified models submitted to the Challenge ([http://www.doi.org/10.7303/syn21445941.1](http://www.doi.org/10.7303/syn21445941.1)). The key components of the top-performing models are listed in Table 1 and summarized below.

**Team Q.E.D model**

To enable a fine-grained discrimination of binding affinities between similar targets (e.g., kinase family members), the team Q.E.D explicitly introduced similarity matrices of compounds and targets as input features into their regression model. The regression model was implemented as an ensemble version (uniformly averaged predictor) of 440 CGKronRLS regressors\(^{24,25}\), but with different choices of regularization strengths [0.1, 0.5, 1.0, 1.5, 2.0], training epochs [400, 410, …, 500], and similarity matrices: the protein similarity matrix was derived based on the normalized striped Smith-Waterman alignment scores\(^{26}\) between full protein sequences ([https://github.com/mengyao/Complete-Striped-Smith-Waterman-Library](https://github.com/mengyao/Complete-Striped-Smith-Waterman-Library)). Eight different alternatives of compound similarity matrices were computed using both Tanimoto and Dice similarity metrics for different variants of 1024-bit Morgan fingerprints\(^{27}\) ('radius' [2, 3] and ‘useChirality’ [True, False], implementation available at [https://github.com/rdkit/rdkit](https://github.com/rdkit/rdkit)). Unlike the baseline method, which used only the available pK\(_{d}\) values from DTC for training, the team Q.E.D model extracted 16945 pK\(_{d}\), 53894 pK\(_{i}\) and 3301 pEC\(_{50}\) values from DTC. After merging the same compound-kinase pairs from different studies by computing their medians, 60462 affinity values between 13608 compounds and 527 kinases were used as the training data.

**Team DMIS_DK model**

Team DMIS_DK built a multi-task Graph Convolutional Network (GCN) model based on 953521 bioactivity values between 474875 compounds and 1474 proteins extracted from DTC and BindingDB. Three types of bioactivities were considered, that is, pK\(_{d}\), pK\(_{i}\), and pIC\(_{50}\). Median was computed if multiple bioactivities were present for the same compound-protein pair. Multi-task GCN model was designed to take compound SMILES strings as an input, which were then converted to molecular graphs using RDKit python library ([http://www.rdkit.org](http://www.rdkit.org)). Each node (i.e. atom) in a molecular graph was represented by a 78-dimensional feature vector, including the information of atom symbol, implicit valence, aromaticity, number of bonded neighbors in the graph, and hydrogen count. No protein descriptors were utilized. The final model was an ensemble of four multi-task GCN architectures described in the Supplementary writeups ([http://www.doi.org/10.7303/syn21445941.1](http://www.doi.org/10.7303/syn21445941.1)). For the Challenge submission, the binding affinity predictions from the last K epochs were averaged, and then the average was taken over the 12 multi-task GCN models (four different architectures with three different weight initializations). Hyper-parameters of the multi-task GCN models were selected based on the performance on a hold-out set extracted from the training data. The GCN models were implemented using PyTorch Geometric (PyG) library\(^{28}\).
Team AI Winter is Coming model

Team AI Winter is Coming built their prediction model using Gradient Boosted Decision Trees (GBDT) implemented in XGBoost algorithm. Training dataset included 600000 pK$_{d}$, pK$_{i}$, pIC$_{50}$, and pEC$_{50}$ values extracted from DTC and ChEMBL (version 25), considering only compound-protein pairs with ChEMBL confidence score of 6 or greater for 'binding' or 'functional' human kinase protein assays. For a given protein target, replicate compounds with different bioactivities in a given assay (differences larger than one unit on a log scale) were excluded. For similar replicate measurements, a single representative assay value was selected for inclusion in the training dataset. Each compound was characterized by a 16000-dimensional feature vector being a concatenation of four ECFP fingerprints with a length set to of 5, 7, 9, and 11. No protein descriptors were used in the XGBoost algorithm. A separate model for each protein target was trained using nested cross-validation (CV), where inner loops were used to perform hyperparameter optimisation and recursive feature elimination. The final binding affinity prediction was calculated as an average of the predictions from the cross-validated models based on five outer CV loops.

Mean ensemble model construction

Ensemble models were generated by combining the best-scoring Round 2 predictions from each team. We iteratively combined models starting from the highest scoring Round 2 prediction (e.g. ensemble #1 - highest scoring prediction, ensemble #2 - 2 highest scoring, ensemble #3 - 3 highest scoring, and so on) for all 54 Round 2 submissions. Three types of ensembles were created using arithmetic mean, median, and rank-weighted summarization approaches. The rank-weighted ensemble was calculated by multiplying each set of predictions by the total number of submissions plus 1 minus the rank of the prediction file, summing these weighted predictions, and then dividing by the sum of the multiplication factors. The 54 ensemble predictions for each of the 3 summary metrics were bootstrapped and Bayes factors were calculated as previously described to determine which models were substantially different than the top ranked submission.

Estimating the expected inhibition levels

The KINOMEscan assay protocol utilized for both the single-dose and dose-response assays is based on competitive binding assays, where the maximum compound concentration tested was 1000 nM in both of the assays. For a given compound-kinase pair, the K$_{d}$ values calculated from the dose-response assay were then used to estimate the expected single-dose %inhibition level (at 1000 nM of compound) using the conventional ligand occupancy formula:

\[
\% \text{ligand occupancy/expected } \% \text{inhibition} = \frac{\text{Maximum ligand concentration}}{\text{Maximum ligand concentration (M) + Estimated Kd (M)}}
\]

where \( \text{Maximum ligand concentration} = 1e-06 \text{ M} \)

The expected %inhibition values based various measured pK$_{d}$ levels are shown in the table:
| Measured pK<sub>d</sub> | Measured K<sub>d</sub> [M] | Expected inhibition [%] |
|----------------------|-------------------------|-------------------------|
| 3                    | 1e^{-03}                | 0                       |
| 4                    | 1e^{-04}                | 1                       |
| 5                    | 1e^{-05}                | 10                      |
| 6                    | 1e^{-06}                | 50                      |
| 7                    | 1e^{-07}                | 91                      |
| 8                    | 1e^{-08}                | 99                      |
| 9                    | 1e^{-09}                | 100                     |

**Activity classification analyses**

Standard confusion matrix was constructed using the measured pK<sub>d</sub> values to define the true positive and true negative classes for the 394 pairs in Round 2, using either pK<sub>d</sub> > 6 and pK<sub>d</sub> > 7 for indicating true positive activity, and the predicted positive and negative classes for these pairs were defined based on either the single-dose activity measurement, using inhibition cut-off of 80%, or the Q.E.D model-predicted pK<sub>d</sub> values, using the same activity thresholds as with the measured pK<sub>d</sub> values (i.e., either pK<sub>d</sub> = 6 or pK<sub>d</sub> = 7). Positive predictive value (PPV) and false discovery rate (FDR) were calculated as classification performance scores.

To carry out a more systematic analysis of prediction accuracies, the 394 pairs in Round 2 were ranked both using Q.E.D model-predicted pK<sub>d</sub> values and the measured single-dose %inhibition values, and then these rankings were compared against the ground-truth activity classification based on the dose-response measurements (using both pK<sub>d</sub> > 6 and pK<sub>d</sub> > 7 for indicating true positive activity). The results were visualized using both receiver operating characteristic (ROC) and precision-recall (PR) curves, implemented in pROC and pRROC R-packages, respectively. The area under the ROC and PR curves was calculated as summary classification performance.

**Data and code availability**

The Challenge test data will be made available at DTC (https://drugtargetcommons.fimm.fi/). The Docker containers of the best-performing teams are available on the Synapse project for this Challenge (www.doi.org/10.7303/syn15667962). The codes for reproducing the results and figures are available at GitHub (https://github.com/Sage-Bionetworks/IDG-DREAM-Challenge-Analysis/). Key R packages used for this work beyond those mentioned elsewhere in this section include tidyverse and synapse; all packages used and their versions can be found in the renv lockfile in the previously mentioned GitHub repository.
Acknowledgements

The authors thank the IDG Kinase Data and Resource Generation Center for providing the unpublished target activity data for the Challenge Rounds 1 and 2, Olle Hansson (FIMM) for technical assistance with DrugTargetCommons, Tianduanyi Wang (FIMM) for his help with the baseline submissions, Anna Goldenberg (University of Toronto, Canada) and Chloe-Agathe Azencott (Institut Curie, France) for organizing the DREAM Idea Challenge, and Barbara Rieck and Ladan Naghavian for the bioactivity profiling at DiscoverX (Eurofins Corporation).

Funding:

TA: Academy of Finland (grants 310507, 313267), the Cancer Society of Finland, the Sigrid Jusélius Foundation. CW, TW, DD: National Institutes of Health (1U24DK116204-01). The SGC is a registered charity that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (ULTRA-DD 115766), Wellcome Trust, Janssen, Merck Kga, Merck Sharp & Dohme, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, and Takeda. O.I. acknowledges support from the National Science Foundation (NSF CHE-1802789), and Eshelman Institute for Innovation (EII) awards. M.P. acknowledges The Molecular Sciences Software Institute (MoISSI) Software Fellowship and NVIDIA Graduate Fellowship. We gratefully acknowledge the support and hardware donation from NVIDIA Corporation. JG acknowledges support from the National Institutes of Health (U54OD020353).

IDG-DREAM Drug Kinase Binding Prediction Challenge Consortium members:

User oselot: Mehmet Tan; **Team N121**: Chih-Han Huang, Edward S. C. Shih, Tsai-Min Chen, Chih-Hsun Wu, Wei-Quan Fang, Jhih-Yu Chen, and Ming-Jing Hwang; **Team Let_Data_Talk**: Xiaokang Wang, Marouen Ben Guebila, Behrouz Shamsaei, Sourav Singh; User thinng: Thin Nguyen; **Team KKT**: Mostafa Karimi, Di Wu, Zhangyang Wang, Yang Shen; **Team Boun**: Hakime Öztürk, Elif Ozkirimli, and Arzucan Özgür; **Team Aydin**: Zafer Aydin, Halli Ibrahim Bilgin; **Team KinaseHunter**: Hansaim Lim, Lei Xie; **Team AmsterdamUMC-KU-team**: Georgi K. Kanev, Albert J. Kooistra, Bart A. Westerman; **Team DruginaseLearning**: Panagiotis Terzopoulos, Konstantinos Ntagiantas, Christos Fotis, Leonidas Alexopoulos; **Team KERMIT-LAB - Ghent University**: Dimitri Boeckxerts, Michiel Stock, Bernard De Baets, Yves Briers; **Team QED**: Fangping Wan, Shuya Li, Yunan Luo, Hailin Hu, Jian Peng, Jianyang Zeng; **Team METU_EM BLELI_CROSSBAR**: Tunca Dogan, Ahmet S. Rifaioglu, Heval Atas, Rengul Cetin Atalay, Volkan Atalay, Maria J. Martin; **Team DMIS_DK**: Sungjoon Park, Minji Jeon, Sunkyu Kim, Junhyun Lee, Seongjun Yun, Bumsoo Kim, Buru Chang, Jaewoo Kang; **Team AI Winter is Coming**: Mariya Popova, Stephen Capuzzi, Alexandr Isayev; **Team hulab**: Gábor Turu, Ádám Misák, Bence Szalai, László Hunyady; **Team ML-Med**: Matthias Lienhard, Paul
Prasse, Ivo Bachmann, Julia Ganzlin, Gal Barel, and Ralf Herwig, **Team Prospectors:** Davor Oršolić, Bono Lučić, Višnja Stepanić, Tomislav Šmuc, **Organizers:** Anna Cichonska, Balaguru Ravikumar, Robert J Allaway, Michael Mason, Andrew Lamb, Zia-ur-Rehman Tanoli, Kristen Dang, Tudor I. Oprea, Avner Schlessinger, David H. Drewry, Gustavo Stolovitzky, Krister Wennerberg, Justin Guinney, Tero Aittokallio

**References**

1. Arrowsmith, C. H. *et al.* The promise and peril of chemical probes. *Nat. Chem. Biol.* **11**, 536–541 (2015).

2. Santos, R. *et al.* A comprehensive map of molecular drug targets. *Nat. Rev. Drug Discov.* **16**, 19–34 (2017).

3. Fabian, M. A. *et al.* A small molecule-kinase interaction map for clinical kinase inhibitors. *Nat. Biotechnol.* **23**, 329–336 (2005).

4. Davis, M. I. *et al.* Comprehensive analysis of kinase inhibitor selectivity. *Nat. Biotechnol.* **29**, 1046–1051 (2011).

5. Elkins, J. M. *et al.* Comprehensive characterization of the Published Kinase Inhibitor Set. *Nat. Biotechnol.* **34**, 95–103 (2016).

6. Mendez, D. *et al.* ChEMBL: towards direct deposition of bioassay data. *Nucleic Acids Res.* **47**, D930–D940 (2019).

7. Gilson, M. K. *et al.* BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. *Nucleic Acids Res.* **44**, D1045-1053 (2016).

8. Oprea, T. I. *et al.* Unexplored therapeutic opportunities in the human genome. *Nat. Rev. Drug Discov.* **17**, 317–332 (2018).

9. Tang, J. *et al.* Drug Target Commons: A Community Effort to Build a Consensus Knowledge
Base for Drug-Target Interactions. *Cell Chem. Biol.* **25**, 224-229.e2 (2018).

10. Omberg, L. *et al.* Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. *Nat. Genet.* **45**, 1121–1126 (2013).

11. Drewry, D. H. *et al.* Progress towards a public chemogenomic set for protein kinases and a call for contributions. *PLOS ONE* **12**, e0181585 (2017).

12. Cichonska, A. *et al.* Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors. *PLOS Comput. Biol.* **13**, e1005678 (2017).

13. Wells, C. I., Kapadia, N. R., Couñago, R. M. & Drewry, D. H. In depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the Nek family of kinases. *MedChemComm* **9**, 44–66 (2018).

14. Ertl, P. Cheminformatics Analysis of Organic Substituents: Identification of the Most Common Substituents, Calculation of Substituent Properties, and Automatic Identification of Drug-like Bioisosteric Groups. *J. Chem. Inf. Comput. Sci.* **43**, 374–380 (2003).

15. Reymond, J.-L. & Awale, M. Exploring Chemical Space for Drug Discovery Using the Chemical Universe Database. *ACS Chem. Neurosci.* **3**, 649–657 (2012).

16. Vamathevan, J. *et al.* Applications of machine learning in drug discovery and development. *Nat. Rev. Drug Discov.* **18**, 463–477 (2019).

17. Marbach, D. *et al.* Wisdom of crowds for robust gene network inference. *Nat. Methods* **9**, 796–804 (2012).

18. Eduati, F. *et al.* Prediction of human population responses to toxic compounds by a collaborative competition. *Nat. Biotechnol.* **33**, 933–940 (2015).

19. Saez-Rodriguez, J. *et al.* Crowdsourcing biomedical research: leveraging communities as innovation engines. *Nat. Rev. Genet.* **17**, 470–486 (2016).

20. Guinney, J. & Saez-Rodriguez, J. Alternative models for sharing confidential biomedical
data. *Nat. Biotechnol.* **36**, 391–392 (2018).

21. Neto, E. C. *et al.* Reducing overfitting in challenge-based competitions. *ArXiv Prepr.* ArXiv160700091 (2016).

22. Pahikkala, T. *et al.* Toward more realistic drug-target interaction predictions. *Brief. Bioinform.* **16**, 325–337 (2015).

23. Guha, R. Chemical Informatics Functionality in R. *J. Stat. Softw.* **18**, 1–16 (2007).

24. Airola, A. & Pahikkala, T. Fast Kronecker Product Kernel Methods via Generalized Vec Trick. *IEEE Trans. Neural Netw. Learn. Syst.* **29**, 3374–3387 (2018).

25. Pahikkala, T. & Airola, A. RLScore: Regularized Least-Squares Learners. *J. Mach. Learn. Res.* **17**, 1–5 (2016).

26. Zhao, M., Lee, W.-P., Garrison, E. P. & Marth, G. T. SSW library: an SIMD Smith-Waterman C/C++ library for use in genomic applications. *PloS One* **8**, e82138 (2013).

27. Rogers, D. & Hahn, M. Extended-Connectivity Fingerprints. *J. Chem. Inf. Model.* **50**, 742–754 (2010).

28. Fey, M. & Lenssen, J. E. Fast Graph Representation Learning with PyTorch Geometric. *ArXiv190302428 Cs Stat* (2019).

29. Chen, T. & Guestrin, C. XGBoost: A Scalable Tree Boosting System. in *Proceedings of the 22Nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining* 785–794 (ACM, 2016). doi:10.1145/2939672.2939785.

30. Robin, X. *et al.* pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* **12**, 77 (2011).

31. Grau, J., Grosse, I. & Keilwagen, J. PRROC: computing and visualizing precision-recall and receiver operating characteristic curves in R. *Bioinforma. Oxf. Engl.* **31**, 2595–2597 (2015).
32. Wickham, H. et al. Welcome to the Tidyverse. *J. Open Source Softw.* **4**, 1686 (2019).

33. Hoff, B. & Ladia, K. *synapser: R language bindings for Synapse API*. (2019).